Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CBX7 | O95931 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635018 | 0.90 | PTGDR2 (0.41) | ALDH1A1CYP3A4CYP2C9CBX7TP53 | |
| SCHEMBL4634714 | 0.81 | POLB (0.52) | ALDH1A1CYP3A4KMT2AMEN1FKBP1A | |
| SCHEMBL4633977 | 0.81 | MEN1 (0.47) | ALDH1A1CBX7KMT2AMEN1MAPT | |
| SCHEMBL4634108 | 0.81 | ENPP2 (0.44) | ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4635527 | 0.80 | FKBP1A (0.44) | ALDH1A1HSD17B10KMT2AMEN1FKBP1A | |
| SCHEMBL4634824 | 0.80 | MDH1 (0.48) | ALDH1A1HSD17B10KMT2AMEN1FKBP1A | |
| SCHEMBL5060127 | 0.79 | ALDH1A1 (0.70) | ALDH1A1CYP3A4CYP2C9HSD17B10KMT2A | |
| SCHEMBL4635591 | 0.78 | ENPP2 (0.61) | ALDH1A1KMT2AMEN1FKBP1ASMN1; SMN2 | |
| SCHEMBL4634732 | 0.78 | CYP2C9 (0.47) | ALDH1A1CYP3A4CYP2C9KMT2AMEN1 | |
| SCHEMBL5674679 | 0.78 | SMN1; SMN2 (0.42) | PTGDR2MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | claimed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | claimed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | claimed |
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | CCR1, CCR2, CCR3 | ALDH1A1 296/4885CYP3A4 1207/4885CYP2C9 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.